Pre-synaptic dopaminergic deficit in a patient with familial FTD
Objective: Clinical description of a patient with familial FTD with a rapidly progressive parkinsonism. Background: FTD typically presents with behavioral and cognitive deficits, but extrapyramidal…Atypical and slowly progressive FTDP-17 caused by MAPT p.R406W mutations – similarities to AD and PSP.
Objective: We compiled clinical data of a new kindred with the MAPT c.1216C>T (p.Arg406Trp; R406W) mutation and systematically reviewed previously described cases with this mutation.…PBB3 Imaging in Parkinsonian disorders: evidence for binding to abnormally aggregated proteins in addition to tau proteins
Objective: To study selective regional binding for tau pathology in vivo, using PET with [11C]PBB3 ([11C]methylamino pyridin-3-yl buta-1,3-dienyl benzo[d]thiazol-6-ol) in tauopathies, and in conditions not…Tau dysfunction in the basal ganglia of a mouse model of tauopathy related to PSP
Objective: Determine motor coordination and neurochemical phenotypes in the basal ganglia of mice lacking the Tau protein or expressing an abnormal content of Tau isoforms.…“Words untold”
Objective: To highlight the salient clinical and pathologic features of primary progressive apraxia of speech through a clinical case presentation. Background: Apraxia of speech is…Dorsal simultanagnosia as a cortical sign in the tauopathy spectrum
Objective: Clinical characterization of a tauopathy spectrum patient. Background: In recent years phenotypic overlap has been demonstrated between patients with progressive supranuclear palsy (PSP) pathology…FYN expression is associated with regulatory region genetic variation
Objective: The hypothesis of this investigation was that FYN expression and promoter activity are significantly influenced according to genetic content. The objective of this investigation…Clinical predictors of progressive supranuclear palsy (PSP) pathology in PSP syndrome
Objective: To elucidate specific clinical features of progressive supranuclear palsy (PSP) pathology in PSP syndrome. Background: PSP syndrome (PSPS) is the clinical hallmark of PSP;…Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity
Objective: To identify disease-modifying therapy for LRRK2-G2019S parkinsonism. Background: Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of Parkinson's disease (PD) without…Defining the pathology underlying cortico-basal syndrome: A European study
Objective: To understand how clinical and biological features can help us define and explain the varying pathology that underlies corticobasal syndrome (CBS). Background: Corticobasal degeneration…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.